Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease

Annals of Oncology

Volumn 17, Issue 10, 2006, Pages 1497-1503

  Colleoni, Marco ^a   Rotmensz, N ^a   Peruzzotti, G ^a   Maisonneuve, P ^a   Orlando, L ^a   Ghisini, R ^a   Viale, G ^a,b   Pruneri, G ^a   Veronesi, P ^a,b   Luini, A ^a   Intra, M ^a   Cardillo, A ^a   Torrisi, R ^a   Rocca, A ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Endocrine responsiveness; Prognostic features; Very young women

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GROUPS BY AGE; HORMONE RESPONSE; HUMAN; LYMPH NODE; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT CARE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 33749600677     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl145     Document Type: Article

References (28)

1. Walker RA, Lees E, Webb MB et al. Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer 1996; 74: 1796-1800.
2. Chung M, Chang HR, Bland KI et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996; 77: 97-103.
3. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: The effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 1994; 16: 69-77.
4. Kroman N, Jensen MB, Wohlfahrt J et al. Factors influencing the effect of age on prognosis in breast cancer: Population based study. B Med J 2000; 320: 474-478.
5. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: Are there age differentials? J Natl Cancer Inst Monogr 1994; 16: 35-42.
6. Goldhirsch A, Gelber RD, Yothers G et al. Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr 2001; 30: 44-51.
7. Han W, Kim SW, Park IA. Young age: An independent risk factor for disease-free survival in women with operable breast cancer BMC Cancer 2004; 4: 82.
8. Biganzoli E, Boracchi P, Coradini D et al. Prognosis in node-negative primary breast cancer: A neural network analysis of risk profiles using routinely assessed factors. Ann Oncol 2003; 14: 1484-1493.
9. Viale G, Bosari S, Mazzarol G et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999; 85: 2433-2438.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer. Histopathology 1991; 19: 403-410.
11. Rosen PP, Oberman HA. Tumors of the mammary gland. Washington DC, Armed Forces Institute of Pathology, 1993.
12. Colleoni M, Orvieto E, Nolè F et al. Prediction of Response to primary chemotherapy for operable breast cancer Eur J Cancer 1999; 35: 574-579.
13. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
14. Colleoni M, Gelber S, Goldhirsch A et al. Tamoxifen after adjuvant chemotherapy for premenopausal patients with lymph-node positive breast cancer: International Breast cancer Study Group Trial 13. J Clin Oncol 2006; 20: 1332-1341.
15. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinelnode biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553.
16. Goldhirsch A, Wood WC, Senn HJ et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995; 87: 1441-1445.
17. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
18. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
19. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496.
20. Colleoni M, Litman HJ, Castiglione-Gertsch M et al. Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 2002; 86: 1705-1714.
21. Northouse LL. Breast cancer in younger women: Effects on interpersonal and family relations. J Natl Cancer Inst Monogr 1994; 16: 183-190.
22. Surbone A, Petrek JA. Childbearing issues in breast carcinoma survivors. Cancer 1997; 79: 1271-1278.
23. Aebi S, Gelber S, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869-1874.
24. Parulekar WR, Day AG, Ottaway JA et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol 2005; 23: 6002-6008.
25. Davidson NE, O'Neill AM, Vukov A M et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results From INT 0101 (E5188). J Clin Oncol 2005; 23: 5973-5982.
26. Francis P, Fleming G, Nasi ML, Pagani O, Perez E, Walley B for the International Breast Cancer Study Group (IBCSG): Breast International Group (BIG): North American Breast Intergroup. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: The SOFT, TEXT, and PERCHE Trials. The Breast 2003; 12 (Suppl 1): S44 (abstr P104).
27. Colleoni M, Gelber S, Coates AS et al. International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001; 19: 4141-4149.
28. Gruvberger S, Ringner M, Chen Y et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61: 5979-84.